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Abstract
Arrhythmogenic ventricular cardiomyopathy (AVC) is 
generally referred to as arrhythmogenic right ventricu-
lar (RV) cardiomyopathy/dysplasia and constitutes 
an inherited cardiomyopathy. Affected patients may 
succumb to sudden cardiac death (SCD), ventricular 
tachyarrhythmias (VTA) and heart failure. Genetic 
studies have identified causative mutations in genes 
encoding proteins of the intercalated disk that lead to 
reduced myocardial electro-mechanical stability. The 
term arrhythmogenic RV cardiomyopathy is somewhat 
misleading as biventricular involvement or isolated left 
ventricular (LV) involvement may be present and thus a 
broader term such as AVC should be preferred. The di-
agnosis is established on a point score basis according 
to the revised 2010 task force criteria utilizing imaging 
modalities, demonstrating fibrous replacement through 
biopsy, electrocardiographic abnormalities, ventricu-
lar arrhythmias and a positive family history including 
identification of genetic mutations. Although several 
risk factors for SCD such as previous cardiac arrest, 
syncope, documented VTA, severe RV/LV dysfunction 
and young age at manifestation have been identified, 
risk stratification still needs improvement, especially in 
asymptomatic family members. Particularly, the role 
of genetic testing and environmental factors has to be 
further elucidated. Therapeutic interventions include re-
striction from physical exercise, beta-blockers, sotalol, 
amiodarone, implantable cardioverter-defibrillators and 
catheter ablation. Life-long follow-up is warranted in 
symptomatic patients, but also asymptomatic carriers 
of pathogenic mutations.
© 2014 Baishideng Publishing Group Co., Limited. All rights 
reserved.
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Core tip: This manuscript constitutes an updated over-
view about arrhythmogenic ventricular cardiomyopathy 
(AVC) and describes well the paradigm shift in the un-
derstanding of AVC from an isolated right-sided entity 
to biventricular disease that can present with multiple 
facets. The most recent advances in molecular and 
clinical research are discussed, with particular focus on 
genetic novelties and risk stratification. We believe that 
this review will help clinicians to better understand the 
pathomechanisms that lead to AVC, its diagnosis and 
state-of-the-art therapeutic decision making.
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INTRODUCTION
Arrhythmogenic ventricular cardiomyopathy (AVC), as 
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recently re-named by the Heart Rhythm Society (HRS) 
and the European Heart Rhythm Association (EHRA) 
consensus statement paper[1], is generally referred to as 
arrhythmogenic right ventricular cardiomyopathy/dys-
plasia (ARVC/D), constituting a hereditary cardiomy-
opathy usually with an autosomal-dominant inheritance 
pattern. Its first description by Giovanni Maria Lancisi, 
the Pope’s physician, dates back to 1736 in his book “De 
Motu Cordis et Aneurysmatibus”[2]. The first comprehen-
sive description of  ARVC/D by Guy Fontaine in 1978 
marks a milestone for our current understanding of  this 
heterogeneous disease[3]. Initially, ARVC/D was thought 
to be an embryological aberration, such as Uhl’s anomaly 
leading to the original designation of  dysplasia[4]. How-
ever, further research shed light on the pathophysiology 
of  ongoing genetically determined myocardial atrophy 
that did not support the theory of  a congenital myocar-
dial absence. Thus, in 1995, ARVC/D was assigned to 
the World Health Organization’s definition and classifica-
tion of  primary cardiomyopathies[5]. Autopsy studies have 
been crucial in understanding AVC. Progressive atrophy 
of  the ventricular musculature due to cumulative myocyte 
loss and infiltration by fibrous and adipose tissue can be 
observed.
The right ventricle (RV) is primarily affected in AVC, 
representing the most common form known as ARVC/D, 
and thus can be referred to as classic AVC[6]. At a later 
stage, the left ventricle (LV) can also be involved and is 
often associated with severe disease and a worse progno-
sis[7]. Advanced molecular genetic studies have identified 
causative mutations in genes encoding proteins of  the 
intercalated disk, mainly desmosomal proteins[8] that lead 
to reduced electrical and mechanical stability of  the myo-
cardium[9,10]. Subsequent myocardial inflammation, apop-
tosis and necrosis may occur. Some of  these histological 
changes are currently discussed as potential cases of  
myocarditis mimicking AVC[11-14]. Because of  the genetic 
basis and the many facets of  the disease, the term “ARVC” 
is somewhat misleading. Particularly as biventricular in-
volvement and less often isolated LV involvement may 
be present in a substantial proportion of  patients[15], a 
broader term such as “arrhythmogenic cardiomyopathy” 
should be preferred, as already suggested by Gallo et al[16] 
almost 20 years ago, and as recently proposed by the HRS 
and the EHRA[1]. However, the cardiology community is 
still reluctant to accept the proposed new nomenclature, 
probably because RV involvement constitutes a hallmark 
of  the disease and non-classic forms are difficult to dis-
tinguish from non-ischemic dilated cardiomyopathies.
EPIDEMIOLOGY
In most parts of  the world, phenotypic expression is 
more common in men than in women (2-3:1)[17,18]. AVC 
commonly manifests during late childhood or adoles-
cence but can also emerge in the elderly[19,20]. With a gen-
eral prevalence of  1:2000, which can be higher in certain 
geographical regions with enhanced genetic prevalence 
such as the Veneto region or the Greek island Naxos, it 
is not so rare[21,22]. Recent data indicates that the preva-
lence is even higher than initially estimated[23]. AVC is 
recognized as a leading cause of  sudden cardiac death 
(SCD) in young adults ≤ 35 years of  age and may ac-
count for up to 10% of  cardiovascular deaths in the < 
65 age group[24,25]. Of  note, in one series from northern 
Italy, AVC accounted for up to 22% of  SCD in all young 
adults ≤ 35 years of  age[26-29]. AVC usually first manifests 
with ventricular tachyarrhythmias (VTA) or SCD. In its 
most common form ARVC/D, ventricular arrhythmias 
originate in the RV and thus have left bundle branch 
block (LBBB) morphology[28,30]. Less often, the primary 
manifestation can be heart failure without symptomatic 
arrhythmias. As LV function is often preserved at early 
stages, ventricular tachycardia (VT) may be asymptomatic 
as far as it does not degenerate into ventricular fibril-
lation (VF)[29]. An early concealed phase without gross 
structural abnormalities is unique among the primary 
cardiomyopathies. On the contrary, in hypertrophic 
cardiomyopathy, arrhythmic risk can be ascribed to the 
underlying myocardial disarray. In dilated cardiomyopathy 
(DCM), arrhythmias generally concur with significant LV 
systolic dysfunction[31]. Of  note, early AVC may resemble 
myocardial channelopathies, such as Brugada syndrome 
(Bs)[32], thus making correct diagnosis and risk stratifica-
tion difficult.
DISEASE SUBTYPES
Classification of  AVC into three different subtypes is 
evolving. AVC in its classic right-dominant form is the 
most common and best known and referred to as ARVC/
D. The non-classic forms were first described by patholo-
gists on autopsy studies and in isolated clinical case re-
ports[33,34]. Through intensive in vivo characterization of  
affected families, a link to hereditary mutations of  the 
intercalated disk was established[35-37]. LV involvement is 
increasingly described with a prevalence of  up to 76% 
of  cases, which may be attributed to improved diagnostic 
methods such as genetic testing, high-resolution contrast-
enhanced cardiac magnetic resonance tomography (CMR), 
and recently the new technology of  echocardiographic 
strain imaging[38]. The proposed classification below is 
simplistic since due to genetic heterogeneity and epigen-
etic factors, a phenotypic continuum with right- and left-
dominant subtypes at opposite ends has to be assumed.
In classic right-dominant ARVC, a dilated RV with 
fibro-fatty infiltration with no or only minimal LV in-
volvement can be found at autopsy (Figure 1). This fibro-
fatty infiltration typically begins subepicardially and may 
expand transmurally over time[39]. Papillary muscles and 
trabeculae are generally not involved in this process[25]. 
Yet, fatty infiltration alone does not constitute a pathog-
nomonic sign of  AVC, as a certain amount of  epicardial 
and intramyocardial fat without an increase in fibrous tis-
sue is present in both ventricles, more commonly in the 
RV, of  persons without cardiovascular disease, particu-
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larly in the obese and elderly[17,40,41]. Another consistent 
finding in AVC is myocardial atrophy. Myocardial wall 
thinning, but also thickening, can both be seen on mac-
roscopic examination[22,40]. The subtricuspid region and 
the thin RV outflow tract (RVOT) are particularly prone 
to ventricular bulging and aneurysm formation that is 
present in 20%-50% of  autopsy cases of  ARVC/D[39]. 
The former concept of  early RV apical involvement and 
the term “triangle of  dysplasia” have recently been ques-
tioned[42]. Even although not very specific, ventricular 
aneurysms are strongly associated with the disease. The 
fact that the interventricular septum is rarely affected by 
fibro-fatty infiltration is an important disadvantage of  en-
domyocardial biopsies, usually obtained from the septum, 
which may frequently yield false-negative results[43]. If  an 
affected region can be obtained for histological evalu-
ation, it may reveal both replacement fibrosis, a repair 
mechanism after myocyte loss, and interstitial fibrosis, a 
reactive process, e.g., to inflammation[36,39].
Biventricular AVC is characterized by early and paral-
lel involvement of  both ventricles that can only be visu-
alized by advanced imaging techniques such as contrast 
CMR or strain echocardiography[36,44]. Progressive disease 
is characterized by systolic impairment and biventricular 
dilation with clinical features of  global congestive heart 
failure. In contrast to other cardiomyopathies with bi-
ventricular involvement, ventricular arrhythmias of  both 
right bundle branch block (RBBB) and LBBB configura-
tion are present at an early stage, with around 10% of  
patients presenting with both[31].
Left-dominant AVC (ALVC) has recently been sug-
gested as a distinct form of  AVC and is characterized by 
the early occurrence of  LV involvement, while global 
RV function is preserved[36]. An overlap with idiopathic 
myocardial fibrosis (IMF) accounting for certain SCD 
cases in a post mortem series has been reported[45]. Typi-
cally, IMF features diffuse interstitial and replacement 
fibrosis with a predilection for the inferior LV wall in the 
absence of  coronary artery disease and other structural 
abnormalities. Of  note, myocardial infiltration by adipo-
cytes is lacking in IMF. In biventricular disease or ALVC, 
ventricular arrhythmias may also originate from the LV 
and thus show a RBBB configuration. Structural and 
electrocardiographic (ECG) findings are the left-sided 
analogues to those observed in ARVC/D (Table 1). The 
RV to LV ratio typically remains < 1.0. To better under-
stand ALVC and its clinical course, future investigations 
will be required.
PATHOGENESIS
Genetically-determined disruption of  intercalated-disk 
integrity is a key factor promoting the development 
of  AVC and SCD. This is widely named the “defective 
desmosome” hypothesis[46,47]. Recent data indicates that 
loss of  desmosomal integrity can substantially affect gap 
junctions, sodium channel function and electrical propa-
gation at the micro- and nano-scale, thereby promoting 
ventricular arrhythmias in the absence of  overt structural 
damage[48]. Accordingly, lethal arrhythmias such as VF 
and polymorphic VT often occur during these concealed 
early stages, while sustained monomorphic VT occur at 
later stages, where there is enough substrate for macro-
re-entry. Delmar et al[9] thus have postulated that muta-
tions in desmosomal genes may affect the integrity of  
other molecular complexes that reside in proximity to 
desmosomes, such as connexins and voltage gated sodi-
um channels, and are crucial for electrical synchrony. This 
molecular complex and its interactions have been named 
the cardiac connexome[49,50]. Yet, genetic mutations in gap 
junctions such as connexin-43 have not been associated 
with AVC so far[10,51].
Currently, two theories for the understanding of  pro-
gressive fibro-fatty replacement of  the myocardium exist: 
(1) inflammation as a response to myocardial injury[4,25,39]. 
Lymphocytic interstitial infiltrates surrounding foci of  
necrotic or degenerative myocytes are observed on his-
topathology. Myocyte cell death may occur via apoptosis 
or necrosis underlying chronic inflammation. Acute 
myocyte cell death has also been reported, suggesting 
acute myocarditis during the disease course[52]. Periodic 
exacerbations of  a previously quiescent disease may be 
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Figure 1 Typical pathology findings in arrhythmogenic ventricular cardiomyopathy/dysplasia. A: Macroscopic finding in a patient with arrhythmogenic right 
ventricular cardiomyopathy/dysplasia (ARVC/D). The myocardium of the right ventricular free wall is partially replaced by fibro-fatty tissue (black arrow) that typically 
begins in the epicardial region and at later stages expands transmurally; B: Endomyocardial biopsy from a patient with ARVC/D demonstrating fatty (black arrow) re-
placement of the right ventricular myocardium. Strands of myocardium are still visible (white arrow, heidenhain trichrome, magnification × 60).
5 mm 500 μm
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and proliferation, leading to the hypothesis that desmo-
somal mutations may cause infiltration of  fibroblasts and 
adipocytes from the epicardial cell layer into the myocar-
dium[60]. This hypothesis is consistent with the frequent 
clinical observation that fibro-fatty infiltration progresses 
from the epicardium towards the endocardium.
GENETICS
Analyses of  the first- and second-degree relatives of  
patients suggest that up to 50% of  AVC cases are fa-
milial[61,62]. AVC is most commonly inherited as a Men-
delian autosomal dominant trait with incomplete pen-
etrance[46,47], although two autosomal recessive forms 
have been described[63-65]. To date, 12 different AVC loci 
are reported in the Online Mendelian Inheritance in Man 
(Table 2)[66]. Compound and digenic heterozygosity has 
been recently suggested, indicating that in some cases 
more than one pathogenic allele may be involved in the 
disease process[65,67,68]. As penetrance is incomplete, ge-
netically affected relatives often demonstrate variable and 
mild phenotype and the prevalence of  familial disease 
is often underestimated in clinical practice[31,62]. The fact 
that AVC can be inherited has been known since 1982 
after the description of  24 adult cases, two in the same 
family, by Marcus et al[69]. Six years later, the autosomal 
dominant pattern of  inheritance with incomplete pen-
etrance and variable expression was demonstrated in a 
study of  nine Italian families[26]. As patients with fully 
penetrant cardiomyopathy and readily discernible fea-
tures of  the palms, plantar fascia and hair were clustered 
in families on the Greek island Naxos, an autosomal 
recessive mutation in the desmosomal protein junction 
plakoglobin (JUP) was finally discovered, which became 
known as Naxos disease. Myocytes and epidermal cells 
share similar intercalated disks (desmosomes and fascia 
adherens) and are both exposed to high shear stress, the 
triggered by such inflammatory episodes and are called 
“hot phases” of  AVC. Occasionally, these phases may 
clinically present with chest pain, dynamic ECG changes 
and increased arrhythmic activity[31]. Strenuous physical 
activity can trigger inflammation as mechanical stress to 
the impaired intercalated disk leads to myocyte detach-
ment and myocyte cell death[53]. It is important to keep in 
mind that isolated myocarditis, sarcoidosis, Bs and other 
diseases can mimic AVC[14], which may prompt further 
histological and molecular investigations. If  molecular 
genetic analyses or pedigree analyses of  affected family 
members are not performed, a biopsy specimen may be 
classified as focal myocarditis[36]. Yet, previous studies 
have indicated a link between AVC and a susceptibility 
to viral and bacterial myocarditis, particularly in non-
hereditary forms[54,55]. The prevalence of  viral genome in 
myocardial biopsies from AVC patients is reported with a 
broad range from 0% to 75%, but a causal association is 
difficult to prove. Presence of  enteroviral RNA has been 
reported in tissue from patients with DCM, suggesting 
an innocent bystander role. Nevertheless, viral presence 
may play a secondary yet important role in disease pro-
gression[47]; and (2) apoptosis following disruption of  the 
intercalated disc[56] with electromechanical instability, as 
indicated by detection of  fragmented DNA, expression 
of  protease CPP-32 by immunohistochemistry and posi-
tive Tc-annexin V scintigraphy in vivo[11-14,57,58]. These his-
tological disarrangements create a substrate for electrical 
re-entrant phenomena and delayed ventricular activation 
triggering ventricular arrhythmias. Of  note, as AVC can 
cause ventricular arrhythmias and SCD in the absence 
of  gross macroscopic abnormalities, histological and 
molecular examinations are important to establish a post-
mortem diagnosis[59]. Other investigators observed that 
epicardium-derived cell cultures obtained from neonatal 
hearts lacking plakophilin-2 (PKP2), an important des-
mosomal gene, revealed enhanced cell migration velocity 
Table 1  Characteristics of arrhythmogenic ventricular cardiomyopathy
Classic right dominant form (ARVC/D) Left dominant form
12-lead surface ECG Intraventricular conduction delay in V1-V3 Leftward QRS axis (< 0°)
QRS complex prolongation V1-V3 ε like waves in inferior or lateral leads
ε wave in V1-V3 LBBB
(Incomplete) RBBB Inverted T-waves in infero-lateral leads
Inverted T-waves in V1-V3 Inverted T-waves V1-6 with biventricular involvement
Inverted T-waves in V1-V6 with biventricular involvement -
ST elevation in V1-V3 -
Poor R wave progression
Signal-averaged ECG Late potentials -
Arrhythmia PVC/VT of LBBB configuration PVC/VT of RBBB configuration
Ventricular volumes Mild to severe RV-dilation ± dysfunction Mild to severe LV-dilation ± dysfunction
RV/LV volume ratio ≥ 1.2, increases with disease expression < 1.0
Other imaging abnormalities Regional wall motion abnormalities in RV Regional wall motion abnormalities in LV
RV aneurysms Non-compacted appearance
Fat/LGE in RV myocardium LGE in the  subepicardial and midwall LV myocardium
Genetics Affected genes currently known to be associated with AVC Association with TMEM43 and phospholamban mutations[1]
Adapted from Jacoby et al[84]. ARVC/D: Arrhythmogenic right ventricular cardiomyopathy/dysplasia; ECG: Electrocardiogram; ε: Epsilon; LBBB: Left 
bundle branch block; LGE: Late gadolinium enhancement; LV: Left ventricle; PVC: Premature ventricular contraction; RBBB: Right bundle branch block; 
RV: Right ventricle; VT: Ventricular tachycardia; AVC: Arrhythmogenic ventricular cardiomyopathy; TMEM43: Transmembrane protein 43.
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heart particularly during strenuous physical activity and 
increased cardiac workload. Thus, it has been assumed 
that common genes encoding proteins of  the intercalated 
disk might be responsible for AVC. In 1994, the first 
chromosomal locus (14q23-q24) for autosomal dominant 
AVC was reported in Italy[47]. Linkage analyses shed light 
on its genetic heterogeneity with sequential discovery of  
several loci on chromosomes 1, 2, 3, 6, 10, 12, 14, 17 and 
18 (Table 2). Most frequently, mutations in genes encod-
ing components of  the cardiac desmosome, an important 
protein complex of  the intercalated disk (Figure 2), are 
associated with AVC, resulting in impaired intercalated-
disk integrity[62,67,68]. The pathogenic importance of  
desmosomal mutations was confirmed by electron mi-
croscopy and immunohistochemistry[2,56]. Intercellular 
junctions consist of  a core region that mediates cell-cell 
adhesion and a plaque region that provides attachment 
to the intermediate filaments within the myocyte. Three 
groups of  desmosomal proteins are known: (1) trans-
membrane desmosomal cadherins including desmocollins 
2 and desmogleins 2 (DSG2); (2) desmoplakin (DSP), a 
plakin family protein that attaches directly to intermedi-
ate filaments (desmin in the myocardium); and (3) linker 
proteins such as armadillo family proteins including JUP 
(catenin-γ) and PKP2 that mediate interactions between 
the desmosomal cadherin tails and DSP[70]. In about 80% 
of  cases with confirmed pathogenic mutations, PKP2, 
DSP and DSG2 are altered[22]. Besides desmosomal gene 
mutations, mutations in genes encoding proteins that 
interact with desmosomal proteins were found as well. 
These include: (1) the transforming growth factor β3 that 
conveys cytokine-stimulating fibrosis and modulates cell 
adhesion and growth[52]; (2) the human ryanodine recep-
tor 2 (RyR2) that induces the release of  calcium from the 
myocardial sarcoplasmic reticulum and that is also associ-
ated with catecholaminergic polymorphic VT (CPVT)[71]; 
(3) the transmembrane protein 43 (TMEM43) discovered 
in the Canadian Newfoundland founder population and 
Europe[72] that functions as a PPAR-γ response element, 
an adipogenic transcription factor; (4) the intermedi-
ate filament desmin; (5) the tumor protein 63; and (6) 
recently, titin (TTN) that bridges the sarcomere along its 
longitudinal axis and forms a continuous filament along 
the myofibril[66]. As TTN binds to the transitional junc-
tion of  the intercalated disk, this may explain a functional 
link to the desmosome[66,73,74]. Current molecular studies 
are screening other components of  the desmosome and 
related proteins, such as plectin and pinin (Table 3)[75]. 
NFκB interacting protein-1 is another extra-desmosomal 
gene of  interest, which has been isolated in Poll-Here-
Table 2  Arrhythmogenic ventricular cardiomyopathy 
classification, from OMIMTM Online Mendelian inheritance 
in Man
AVC subtype Chromosome/locus Mode of transmission Encoded protein
ARVC/D 1 14q23-q24 Autosomal-dominant TGFβ3
ARVC/D 2   1q42-q43 Autosomal-dominant RyR2
ARVC/D 3 14q12-q22 Autosomal-dominant -
ARVC/D 4          2q32 Autosomal-dominant TTN
ARVC/D 5          3p23 Autosomal-dominant TMEM43
ARVC/D 6 10p12-p14 Autosomal-dominant -
ARVC/D 7        10q22 Autosomal-dominant -
ARVC/D 8          6p24 Autosomal-dominant DSP
ARVC/D 9        12p11 Autosomal-dominant PKP2
ARVC/D 10        18q12 Autosomal-dominant DSG2
ARVC/D 11        18q12.1 Autosomal-dominant DSC2
ARVC/D 12        17q21 Autosomal-dominant JUP
Naxos disease        17q21 Autosomal-recessive JUP
AVC: Arrhythmogenic ventricular cardiomyopathy; ARVC/D: Arrhyth-
mogenic right ventricular cardiomyopathy/dysplasia; TGF: Transforming 
growth factor; RyR2: Ryanodine receptor 2; TTN: Titin; TMEM43: Trans-
membrane protein 43; DSP: Desmoplakin; PKP2: Plakophilin-2; DSG2: 
Desmoglein-2; DSC2: Desmocollin-2; JUP: Junction plakoglobin.
Outer dense plaque
Desmoplakin
Plakoglobin
Plakophilins Sarcolemma
Gap junction
Intercellular space
Desmocollin
Desmoglein
Intermediate filaments
Figure 2  Molecular model of the desmosome: in the desmosomal complex the intermediate filaments of the cytoskeleton (desmin in the heart) are linked 
to the transmembranous cadherins (desmocollin and desmoglein) via  armadillo proteins (plakoglobin and plakophilin) and desmoplakin. This interaction is 
crucial for myocardial mechanical and electrical stability. Mutations in arrhythmogenic right ventricular cardiomyopathy mostly affect desmosomal proteins.
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ford cattle with recessive AVC and woolly hair coat syn-
drome[76]. Yet, the pathogenic role of  NFκB interacting 
protein-1 mutations in humans has to be demonstrated in 
future studies.
MODIFIER GENES AND ENVIRONMENTAL 
FACTORS
Although a plethora of  pathogenic mutations exists, 
these mutations cannot account for the entire broad 
spectrum of  disease expression. Data from the New-
foundland founder population and populations from 
the Dutch and Swiss ARVC/D registries show a strong 
male predominance of  disease expression[77]. A modi-
fier effect of  testosterone has been discussed. Yet, this 
male predominance has not been confirmed in the Johns 
Hopkins ARVC/D cohort, which may be associated with 
similar exercise levels among males and females in the 
United States. Nevertheless, outcomes were strongly gen-
der dependent in all of  those cohorts, with male gender 
constituting an independent risk factor for adverse out-
comes[37,62,72,78,79]. In one study, 67% of  family members 
showed discordant disease patterns between RV and LV 
involvement[31]. Recent data pointing at the importance 
of  compound and digenic heterozygosity indicates that 
modifier genes may account for residual variation and 
disease severity[68,80]. The first evidence for environmental 
influences in AVC arose from monozygotic twin stud-
ies, where differences were reported in symptom onset, 
structural severity and arrhythmic risk. Strenuous physical 
activity seemed to play an important role in these four 
cases[81]. These preliminary observations were confirmed 
in two recent studies, in which endurance training and 
frequent exercise were associated with earlier disease 
manifestation and disease severity[31,82]. Future studies will 
be crucial to distinguish between pathogenic mutations 
and innocent bystander mutations and to define the role 
of  epigenetic factors in disease manifestation and progres-
sion. As recently proposed by the HRS/EHRA consensus 
statement, genetic testing should only be performed if  the 
signal-to-noise ratio is expected to be > 10[1].
CLINICAL PRESENTATION
AVC has a reported community-based prevalence of  1 in 
2000 and thus cannot be classified as a “rare” disease ac-
cording to the 2007 European definition. These numbers 
reflect the importance of  appropriate diagnostic tools as 
it is often underdiagnosed, particularly in early and mild 
cases. The above mentioned non-classic subtypes are 
usually not considered or misattributed as DCM. Some 
forms mimic myocarditis. Early disease with arrhythmias 
but without overt structural changes may be misjudged 
as idiopathic VT or ventricular ectopy[36,46]. In the elderly, 
AVC is rarely considered as a differential diagnosis, which 
is certainly a false assumption. All these aspects infer that 
real-world prevalence is higher. In the following section, 
we provide an overview of  clinical symptoms and signs 
that shall increase awareness of  the disease, particularly 
in non-classic forms, for timely diagnosis and preven-
tion of  SCD. AVC should be suspected if  the following 
symptoms or signs occur: (1) palpitations; (2) presum-
ably arrhythmic presyncope or syncope; (3) VT with 
LBBB morphology; (4) aborted SCD. Palpitations and 
(pre)syncope are the most frequent symptoms[17]. A high 
clinical suspicion should be raised if  these symptoms cor-
relate with premature ventricular contractions (PVC) or 
VT with LBBB morphology, particularly with a superior 
axis (Figure 3). However, ALVC or biventricular disease 
can present with VT with RBBB morphology or both 
(Table 1, Figure 3). The presence of  monomorphic VT is 
associated with late disease stages, although gross struc-
tural changes are not mandatory[28,83]. Recently, disease 
severity, VT frequency and early onset of  VT have been 
associated with the presence of  common desmosomal 
mutations, particularly if  more than one pathogenic vari-
ant was present[62,67,84]. Up to 25% of  patients present 
with supraventricular tachycardia (SVT), most frequently 
atrial fibrillation, which is associated with male gender, 
increasing age and left atrial enlargement in AVC[85]. SVT 
are very important as they are associated with inappropri-
ate implantable cardioverter defibrillator (ICD) shocks 
Table 3  Future candidate proteins for arrhythmogenic 
ventricular cardiomyopathy
Encoded protein
Components of the desmosome
Plectin
Emerin
Components of the adherens junction
β-catenin
α-catenin
N-cadherin 
Components of the gap junction 
Connexin 43
Myotonic dystrophy protein kinase-1
Laminin receptor-1
Components of dystrophin-glycoprotein complex
Ⅰ
 Ⅱ
 Ⅲ
 aVR
 aVL
 aVF
 V1
 V2
 V3
 V4
 V5
 V6
Figure 3 Monomorphic sustained ventricular tachycardia with left bundle 
branch block morphology and superior axis (Ⅱ, Ⅲ, aVF negative), a major 
criterion for arrhythmogenic right ventricular cardiomyopathy/dysplasia 
according to the revised 2010 task force criteria.
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and an increased risk of  both heart failure and death. 
Furthermore, atrial arrhythmias present at a younger age 
than in the general population[86]. It is not rare that AVC 
first manifests as SCD, with some authors reporting an 
annual incidence of  9%[87]. Whereas some authors report 
that SCD occurs preferentially during strenuous physical 
activity[25,87,88], according to others it may often occur in 
the sedentary state[13,25]. In ARVC/D caused by TMEM43 
mutations, enhanced sympathetic activity as a trigger for 
lethal arrhythmias is established[71]; (5) chest pain with 
or without dynamic ST elevation/T-wave changes on 
12-lead surface ECG ± rise in cardiac biomarkers; and (6) 
presumed DCM with early onset and frequent ventricular 
arrhythmias. Precordial T-wave inversions beyond V1 
after puberty (Table 1, Figure 4) and T-wave inversions in 
the right precordial leads V1-V3 may potentially be be-
nign, particularly before puberty. Their prevalence among 
athletes and sedentary controls is similar[89], suggesting 
that this is not a training-related phenomenon. Accord-
ing to recent recommendations, a further evaluation with 
transthoracic echocardiography (TTE) may be performed 
after puberty. If  imaging is inconclusive, regular follow-
up by serial clinical examinations, ECG and TTE can be 
performed as structural alteration may become apparent 
after several years[90,91]. RV failure with dyspnea and signs 
of  right sided heart failure are rather rare and reported in 
up to 6% of  patients at initial presentation. If  the LV is 
involved, congestive heart failure may occur. Importantly, 
the clinician should be aware that AVC cannot be exclud-
ed by the absence of  structural abnormalities as arrhyth-
mias often occur in the “concealed phase” and structural 
abnormalities may follow after years. In a review report-
ing 37 families with AVC index patients, only 151 of  365 
family members had clinically manifested disease and 17 
family members were healthy despite a pathogenic muta-
tion[28]. Thus, genetic screening of  family members may 
help to identify AVC, although a negative test does not 
exclude it.
DIAGNOSIS
Revised 2010 task force criteria
Currently, no gold standard to establish or exclude the 
diagnosis of  AVC exists. In 2010, the original 1994 task 
force criteria (TFC) for diagnosis of  ARVC/D by Marcus 
et al[92] were revised in order to enhance diagnostic sensi-
tivity and particularly to improve identification of  affect-
ed asymptomatic family members[93]. The importance of  
pathogenic mutations was acknowledged and precise cut-
off  values for imaging and histological evaluation were 
provided. The impact of  these changes is currently being 
evaluated. Some investigators report an increased diag-
nostic yield with the revised TFC[94,95], while others could 
not demonstrate a benefit[96,97]. It is important to keep 
in mind that these TFC only apply to ARVC/D with or 
without LV involvement. The revised TFC assign the 
findings into six categories (Table 4): (1) global and/or 
regional myocardial dysfunction and structural abnormal-
ities; (2) histological characterization; (3) repolarization 
abnormalities on 12-lead surface ECG; (4) depolarization 
abnormalities on 12-lead surface ECG; (5) arrhythmias; 
and (6) family history and genetics.
Definite diagnosis requires 2 major criteria, 1 major 
and 2 minor criteria, or 4 minor criteria from different 
categories. ARVC/D is considered “borderline” if  1 ma-
jor and 1 minor criterion, or 3 minor criteria are present. 
ARVC/D is still “possible” if  1 major criterion or 2 mi-
nor criteria are present. For each individual, comprehen-
sive non-invasive evaluation is necessary. This includes 
a thorough clinical history and examination, pedigree 
analysis, 12-lead surface ECG, TTE with detailed assess-
ment of  the RV, CMR, stress testing in order to induce 
arrhythmias, and Holter ECG monitoring. If  suspicion 
remains high and symptoms are rare, event recorders and 
invasive procedures may be needed.
Physical examination
Fifty percent of  patients will have a normal physical 
exam. The other 50% will show abnormalities such as 
giant a-waves on the jugular veins, tricuspid regurgitation 
murmur, a fixed splitting of  S2, and right-sided S3-S4 at 
the left sternal border with augmentation during inspira-
tion in case of  RV dilation[88,98].
12-lead surface ECG and signal-averaged ECG
An abnormal 12-lead surface ECG will be present in 
about 50% of  patients with ARVC/D. In one study, ECG 
was abnormal in 90% of  patients after a follow-up period 
of  6 years[99]. Abnormalities include epsilon waves, a QRS 
duration ≥ 110 ms in V1-V3, and T-wave inversions in 
the right precordial leads (Figure 4). A prolonged termi-
nal activation duration (measured from the nadir of  the S 
wave until the end of  the QRS complex) in V1-V3 ≥ 55 
ms is considered as a minor criterion for ARVC/D and 
has been reported as the first sign in young asymptomatic 
family members[45,62,100]. However, interpretation of  ECG 
findings, apart from T-wave inversions, significantly var-
Figure 4  Electrocardiographic findings. A 12-lead surface electrocardiogram 
(25 mm/s, 10 mm/mV) showing typical depolarization abnormalities (prolonged 
terminal activation duration in V1-V2, a minor criterion according to 2010 task 
force criteria, long arrows) and repolarization abnormalities (T-wave inversions 
V1-V4 in the absence of complete right bundle branch block, a major criterion 
according to 2010 task force criteria, arrowheads), and premature ventricular 
contractions with two different morphologies (short arrows).
V1
V2
V3
V4
V5
V6
aVR
Ⅰ
Ⅱ
Ⅲ
aVL
aVF
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ies among observers (unpublished data as yet from our 
group). This is particularly true for what is considered 
an epsilon wave. A limitation of  T-wave inversions is the 
fact that they can also be found in healthy individuals, 
patients with anterior ischemia or RV hypertrophy[90,101]. 
A recent study highlighted the importance of  serial ECG 
evaluations as dynamic ECG changes occurred in 23% 
of  patients over a median follow-up period of  34 mo, but 
these were not paralleled by structural abnormalities[102]. 
Fibro-fatty infiltrations disrupt the electrical continuity of  
myocardial fibers. This leads to fragmentation and delay 
of  ventricular depolarization (zig-zag pathways). On the 
surface, this may be visible as QRS fragmentation[103], late 
ventricular potentials of  small amplitude such as epsilon 
waves[104], or late potentials recorded by signal-averaged 
ECG (SAECG)[87,105]. An abnormal SAECG (a minor cri-
terion) indicates progressive disease and may predict VT, 
although a recent study has questioned the latter[28,106]. 
SAECG may not be sensitive enough to detect early 
forms of  AVC[28].
Stress testing
Exercise can induce ventricular arrhythmias and is impor-
tant in patients with suspected AVC. However, VT with 
LBBB morphology and inferior axis can occur in both 
ARVC/D and idiopathic RVOT-VT without underlying 
structural abnormalities[107]. A recent study has proposed 
ECG criteria and a scoring system to distinguish between 
the two entities[108].
Transthoracic echocardiography
In many centers, TTE constitutes the initial imaging tool 
for evaluation of  patients with suspected AVC and for 
screening family members as it is readily available and 
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Table 4  Revised (2010) task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia, adapted 
from Marcus et al [92]
Structural alterations
Major   TTE regional RV akinesia, dyskinesia, or aneurysm and 1 of the following criteria (end diastole)
     PLAX RVOT ≥ 32 mm [(PLAX/BSA) ≥ 19 mm/m2]
     PSAX RVOT ≥ 36 mm [(PSAX/BSA) ≥ 21 mm/m2]
     Or RV fractional area change ≤ 33%
  CMR regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and 1 of the following criteria (end diastole)
     RV end-diastolic volume/BSA ≥ 110 mL/m2 (♂) or ≥ 100 mL/m2 (♀)
     Or RV ejection fraction ≤ 40%
  RV angiography regional RV akinesia, dyskinesia, or aneurysm
Minor   TTE regional RV akinesia, or dyskinesia and 1 of the following criteria (end diastole)
     PLAX RVOT ≥ 29-31mm [(PLAX/BSA) ≥ 16-18 mm/m2]
     PSAX RVOT ≥ 32-35 mm [(PSAX/BSA) ≥ 18-20 mm/m2]
     RV fractional area change > 33%-39%
  CMR regional RV akinesia, dyskinesia, or dyssynchronous RV contraction and 1 of the following criteria (end diastolic)
     RV end-diastolic volume/BSA ≥ 100-109 mL/m2 (♂) or ≥ 90-99 mL/m2 (♀)
     Or RV ejection fraction > 40%-44%
Histopathology (endomyocardial biopsy)
Major   Residual myocytes < 60% by morphometric analysis with fibrous replacement of the RV free wall myocardium ≥ 1 sample, with or 
  without fatty replacement
Minor   Residual myocytes 60%-75% by morphometric analysis with fibrous
  Replacement of the RV free wall ≥ 1 sample
Repolarization abnormalities (> 14 years of age)
Major   T-wave inversions V1-V3 or beyond (in absence of complete RBBB)
Minor   T-wave inversions V1-V2 or V4-V6 (in absence of complete RBBB)
  T-wave inversions V1-V4, if complete RBBB present
Depolarization abnormalities
Major   Epsilon wave (reproducible low-amplitude signals between end of QRS complex to onset of the T-wave) in V1 to V3
Minor   SAECG with late potentials (if QRS complex on standard surface ECG < 110 ms) or terminal activation duration of QRS ≥ 55 ms in V1, V2 or V3
Arrhythmias
Major   VT of LBBB morphology with superior axis
Minor   VT of RVOT configuration, LBBB morphology with inferior axis or of unknown axis
  > 500 PVC per 24 h (holter)
Family history
Major   ARVC/D in a first-degree relative who meets current TFC
  ARVC/D confirmed pathologically at autopsy or surgery in a first-degree relative
  Identification of a pathogenic mutation categorized associated with ARVC/D in an index patient
Minor   Suspected ARVC/D in a first-degree relative-premature SCD (< 35 years of age) due to suspected ARVC/D in a first-degree relative
  ARVC/D confirmed pathologically or by current TFC in second-degree relatives
Definite diagnosis: two major or one major and two minor criteria or four minor from different categories; Borderline diagnosis: one major and one minor 
or three minor criteria from different categories; Possible diagnosis: one major or two minor criteria from different categories. BSA: Body surface area; CMR: 
Cardiac magnetic resonance tomography; LV: Left ventricle; PLAX: Parasternal long-axis view; PSAX: Parasternal short-axis view; RBBB: Right bundle 
branch block; RVOT: Right ventricular outflow tract; RV: Right ventricle, TTE: Transthoracic echocardiogram, PVC: Premature ventricular contraction VT: 
Ventricular tachycardia; SAECG: Signal-averaged electrocardiographic; LBBB: Left bundle branch block; ARVC/D: Arrhythmogenic right ventricular car-
diomyopathy/dysplasia; TFC: Task force criteria; SCD: Sudden cardiac death.
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rapidly informative. It may demonstrate RV enlargement 
or multiple areas of  dilation and regional contraction 
abnormalities, mainly in the subtricuspid region, RVOT 
and RV apex[109]. According to the revised TFC, evalu-
ation and measurements of  the RVOT are crucial for 
diagnosis[110]. The LV can also be affected, particularly in 
non-classic forms displaying hypokinesia and a reduced 
ejection fraction, although in most cases LV structural ab-
normalities are localized in the posterolateral region[111,112]. 
CMR
CMR has emerged as the non-invasive diagnostic tool of  
choice for assessing the RV over the past 15 years[45,113]. 
Besides highly accurate assessment of  right sided vol-
umes, myocardial mass and systolic and diastolic function, 
the contrast-enhanced CMR can reveal intramyocardial 
fibrosis by late gadolinium enhancement (LGE)[114]. Yet, 
intramyocardial fat and fibrosis as diagnostic targets in 
AVC were not integrated in the revised TFC because of  
the limited specificity of  these findings, particularly in the 
absence of  regional wall motion abnormalities, signifi-
cant intra- and inter-observer variability, and the need for 
highly specialized interpreters in visualizing the RV myo-
cardium[45,115,116]. In fact, it can be challenging to be certain 
of  LGE within the RV myocardium because of  the thin 
RV and possible confusion with fat. The main difference 
in CMR criteria compared to the 1994 criteria constitutes 
the quantification of  RV dilation and RV function. CMR 
plays an important role in diagnosing AVC (Figure 5) but 
consensus guidelines for non-classic forms are eagerly 
awaited. Some authors emphasize the importance of  
combining TTE with CMR to increase diagnostic yield. 
New diagnostic tools for detection of  early diastolic and 
systolic abnormalities such as three-dimensional echo-
cardiography, strain echocardiography and CMR tagging 
could facilitate early diagnosis of  ACV[117-120]. The prom-
ising results of  these preliminary studies[121,122] will have to 
be validated in large prospective studies.
RV angiography
RV angiography is considered a very useful test to di-
agnose classic forms of  AVC and to evaluate RV func-
tion[123,124]. Its positive predictive value is above 85%, with 
a negative predictive value of  95%[88]. Technical aspects 
of  the procedure can be found at arvd.org. Good quality 
images allow global and regional analyses of  morphology 
and wall motion. RV angiography also has certain limi-
tations that explain why it is not widely used in clinical 
practice. Clinicians want to offer non-invasive strategies 
without ionising radiation, particularly if  patients are 
young. Additionally, serial follow-up RV angiographies for 
monitoring disease progression are difficult to perform. 
It is important to remember that according to the revised 
2010 TFC, with all three imaging techniques, hypokinesia 
is no longer considered diagnostic.
Electrophysiological study and electroanatomical 
voltage mapping
Arrhythmias can be induced during an electrophysiologi-
cal study (EPS) with programmed ventricular stimula-
tion. Induction of  clinical VT can guide ablation. The 
susceptibility for arrhythmias, arrhythmia detection, ICD 
treatment algorithms and efficacy of  antiarrhythmic 
drugs can be assessed. Electroanatomical voltage map-
ping (EAM) is a technique using electrophysiological 
catheters to measure local myocardial voltages. After 
obtaining several hundred points, a voltage map can be 
reconstructed. According to several studies, healthy RV 
myocardium displays bipolar voltages > 1.5 mV[125-127]. In 
myocardium infiltrated by fibro-fatty tissue, abnormally 
low voltages with a longer duration, splitting and frac-
tionation of  signals can be found. Myocardial voltage 
maps are usually obtained from the endocardium but 
epicardial measurements after puncturing the pericardial 
sac are also feasible. EAM has been shown to be safe and 
to improve outcomes of  VT ablation in ARVC/D[128-131]. 
The diagnostic and prognostic utility of  EAM has not yet 
been implemented in the current TFC. Larger prospec-
tive studies may consolidate the role of  EAM in the diag-
nostic armamentarium[125,132,133].
Endomyocardial biopsy
Endomyocardial biopsy (EMB) was considered the di-
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Figure 5  Regional right ventricular dyskinesia of the right free wall de-
tected by cardiac imaging are considered as a major criterion for right 
ventricular cardiomyopathy/dysplasia according to the revised task force 
criteria if additionally right ventricle dilation or impaired right ventricle 
ejection fraction are present. These cardiac magnetic resonance images (up-
per panel 4-chamber view, lower panel 2-chamber view late sequences) show 
aneurysms of the RV free wall (long arrows), and LV involvement detected by 
a small akinetic region (arrowhead) and late gadolinium enhancement of the 
posterior LV wall (short arrow), confirming biventricular involvement. ARVC/D: 
arrhythmogenic right ventricular cardiomyopathy/dysplasia; RV: Right ventricle; 
LV: Left ventricle.
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agnostic gold standard for AVC for a long time. It may 
allow confirmation of  AVC in an index patient and ex-
clude potential differential diagnoses such as sarcoidosis 
or Chagas disease. However, EMB are commonly taken 
from the thicker RV septum to assure a safe procedure. 
It was recognized that the septum is often spared by 
fibro-fatty infiltration and thus often yields false-negative 
results[132,134]. Nevertheless, septal EMB can identify other 
conditions such as sarcoidosis, myocarditis and IMF. 
EMB from diseased regions is problematic as these re-
gions are often difficult to reach, very thin and sample 
acquisition carries an increased risk of  perforation and 
tamponade[4]. Histological analysis should best be per-
formed by an expert cardiac pathologist who judges the 
amount of  surviving myocytes and fibro-fatty replace-
ment. The results can be allocated as one major or one 
minor criterion according to the revised TFC. As AVC is 
patchy, several biopsies should be obtained. EAM-guided 
biopsies taken from low-voltage areas may improve di-
agnostic yield and better distinguish between myocarditis 
or sarcoidosis[14,125,135]. Serious concerns remain about the 
hazards of  sampling thin areas, although complication 
rates in preliminary studies were low[14]. Moreover, EAM-
guided EMB may be of  limited value in early stages of  
AVC when serious arrhythmias occur in the absence of  
gross structural abnormalities. Additional immunohisto-
chemical staining of  the intercalated disk, e.g., with plako-
globin, may turn into a valuable tool for pathologists in 
the future but results very much depend on the protocols 
used[2]. Confirmation of  typical histological changes by 
cardiac surgery or necropsy can help to confirm the diag-
nosis and exclude differential diagnoses.
Genetic testing
A consensus statement from the HRS and the EHRA 
regarding genetic testing in AVC was published recently[1]. 
The major purposes of  genetic testing are to confirm 
AVC in probands with a high (Class Ⅱa recommenda-
tion, level of  evidence C) or intermediate (at least 1 major 
or 2 minor criteria; Class Ⅱb recommendation, level of  
evidence C) clinical suspicion and to identify genetically-
affected relatives harboring the pathogenic mutation 
(Class Ⅰ recommendation, level of  evidence C), particular-
ly those without overt disease. Genetic testing in probands 
fulfilling only one minor criterion is not recommended. 
A family background and identification of  a pathogenic 
mutation has been demonstrated in up to 50%, while in 
the remaining probands, an underlying familial disease 
with incomplete penetrance cannot be excluded. The 
most common mutations are found in PKP2 (80% of  
mutations in the Dutch and Northern American cohorts) 
and DSP (39% in the Italian cohort)[80], followed by 
DSG2[8,47,62,136,137]. It should be kept in mind that molecu-
lar genetic testing may only support a clinical diagnosis or 
suspicion. A negative test does not rule out AVC, because 
other causal genetic mutations and unknown environ-
mental factors may also cause the disease[47,138]. Pathogen-
ic mutations do not make a diagnosis of  AVC itself, as 
multiple sources of  diagnostic information such as ECG 
changes, ventricular arrhythmias and ventricular abnor-
malities have to be considered[56]. Yet, the identification 
of  pathogenic mutations may be useful in the differential 
diagnosis of  AVC and phenocopies, such as myocarditis, 
idiopathic RVOT tachycardia, DCM, muscular dystro-
phies, IMF or sarcoidosis[35]. Cascade genetic screening 
of  relatives may offer another strategy to serial non-
invasive cardiovascular evaluation of  family members. 
Current guidelines[1,87] do not recommend genetic testing 
for risk stratification and therapeutic decision making in 
AVC because study results regarding the ability of  geno-
typing to detect malignant mutations associated with an 
increased susceptibility to potentially lethal arrhythmias 
have been conflicting[8,62,64,90,139]. Recent large scale stud-
ies[8,62] indicate an association between positive mutation 
carrier status and early disease onset. Thus, genotyping of  
younger family members should strongly be encouraged. 
This might be particularly important for patients carrying 
digenic or compound heterozygote mutations that are 
reported in up to 18% of  the AVC population studied 
and have been associated with a stronger phenotype[1]. 
Issues such as the availability of  genetic counselling in a 
multidisciplinary setting[140], low-probability mutations[136], 
genetic testing for “low-probability” AVC, psychological 
repercussions of  young patients, and costs need to be 
considered before performing genetic screening[75].
DIFFERENTIAL DIAGNOSIS
Idiopathic RVOT-VT is a major non-hereditary differen-
tial diagnosis that has to be distinguished from ARVC/D. 
This is often demanding, particularly in the early stages 
of  AVC[141]. RVOT-VT is not associated with structural 
heart disease and thus has a more benign course. Its eti-
ology is unclear, although in one study a somatic point 
mutation in the inhibitory G protein Gai2 was identified 
by EMB from the arrhythmic focus[142]. In RVOT-VT, 
12-lead surface ECG and SAECG are normal during 
sinus rhythm. It is characterized by repetitive monomor-
phic VT of  a single morphology with LBBB morphology 
and an inferior axis. Similar VT morphologies can be 
found in patients with ARVC/D. 12-lead ECG scoring 
systems to differentiate both types of  VT have recently 
been proposed[108]. In ARVC/D the duration of  the 
QRS complex during VT is usually longer (≥ 120 ms in 
lead Ⅰ)[143]. Notching of  the QRS and precordial transi-
tion in lead V6 may exclusively be seen in ARVC/D[144]. 
RVOT-VT is difficult to induce by programmed ventricu-
lar stimulation during EPS, particularly in the absence 
of  isoproterenol[87]. It responds well to beta-blockers 
or verapamil and ablation after successful mapping is 
usually curative. EAM demonstrates normal voltages. 
CPVT is caused by mutations in the RyR2 gene, which 
has also been described in ARVC/D subtype 2. CPVT 
is characterized by effort-induced polymorphic VT in 
patients with structurally normal hearts. Genetic analysis, 
a positive family history, EAM and EMB can help to dif-
ferentiate AVC and regional myocarditis[14]. Myocardial 
involvement in sarcoidosis can mimic ARVC/D and the 
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current TFC do not reliably distinguish between them. In 
a prospective study of  patients with suspected ARVC/D, 
evaluated by a protocol including EMB, a surprisingly 
high incidence (15%) of  cardiac sarcoidosis was veri-
fied[145]. Sarcoidosis with cardiac involvement thus always 
needs to be considered, particularly if  respiratory and sys-
temic symptoms, high-grade atrioventricular conduction 
block, and no family disease are present. Similar clinical 
presentations and imaging findings can pose a challenge 
in the absence of  histological diagnosis. Features favor-
ing cardiac sarcoidosis include early septal involvement, 
reduced LV function, a wide QRS during VT, right-sided 
apical VT and more inducible forms of  monomorphic 
VT[146]. Diagnosis is usually confirmed by EMB[147]. In 
patients who survive SCD, ischemic heart disease and an 
anomalous origin of  the coronary arteries have to be ex-
cluded. DCM is particularly difficult to distinguish from 
non-classic forms of  AVC. Palpitations, (pre)syncope and 
ventricular arrhythmias are present at an early stage in 
AVC, often in the absence of  gross structural abnormali-
ties, which is usually not the case in DCM. Subepicardial 
LGE on CMR, particularly in the posterobasal LV wall, 
also favors AVC[36]. Atrioventricular conduction block is 
more common in DCM, but mutations in lamin A/C can 
cause AVC with conduction defects[148]. Bs may mimic 
ARVC as RV conduction delay has been demonstrated 
in both and recently a genetic overlap between these two 
entities has been proposed[94,149]. The presence of  gross 
structural abnormalities favors AVC and mutations in 
SCN5A are very rare in AVC. Further differential diag-
noses include RV infarction, pulmonary hypertension, 
congenital left-to-right shunts, Chagas disease and Uhl’s 
disease (congenital hypoplastic RV).
DISEASE COURSE AND PROGNOSIS
Although AVC is a progressive disease, the individual 
disease course can vary considerably. The mortality rate 
is currently estimated to be around 1%-3% per year. In 
one study, after 8 years of  mean follow-up, total mortality 
was approximately 20% and the mean age at death 54 ±
19 years. Most patients died of  progressive heart failure 
(59%) and VTA (29%)[150]. Embolic stroke may lead to 
death in a smaller proportion of  patients.
AVC occurs in four phases[2]: (1) concealed phase, 
during which patients are asymptomatic and structural 
abnormalities are absent or subtle. Nevertheless, AVC can 
present with SCD as the primary manifestation; (2) oc-
currence of  symptomatic arrhythmias; (3) early heart fail-
ure symptoms; and (4) end-stage heart failure necessitat-
ing a ventricular assist device or cardiac transplantation. 
One study has shown that 7% of  AVC patients received 
cardiac transplantation after a mean follow-up period of  
10 years and severe LV involvement is often present in 
this population[7]. Strenuous physical activity often leads 
to early disease manifestation and rapid disease progres-
sion. Young competitive athletes with AVC have a 5-fold 
increased risk of  SCD compared to non-athletes and 
identification of  affected athletes by pre-participation 
screening has substantially reduced mortality in this co-
hort[64,151]. Interestingly, in one study, mutation-carrying 
female relatives were less frequently affected than male 
relatives. This has been interpreted as prevention of  
apoptosis in cardiac myocytes by estradiol but could also 
be related to more life-long physical activity in men[152].
RISK STRATIFICATION
SCD in patients with AVC is difficult to predict and often 
occurs without alarming symptoms. The only reliable 
strategy for SCD prevention is the implantation of  an 
ICD, with an annual incidence of  appropriate ICD inter-
ventions among AVC patients of  5%-22%, demonstrat-
ing its importance for these patients. Thus, in secondary 
prevention after aborted SCD, VF or sustained VT, ICD 
implantation is recommended[87,147]. Besides aborted SCD, 
VF and sustained VT, other potential risk factors for 
SCD or appropriate ICD therapy (a surrogate marker 
for SCD) have been suggested: (1) syncope (DARVIN 2 
study)[93]; (2) left ventricular dysfunction[7,56,153]; (3) young 
age at presentation[62,63,67] and young age per se[47,64]; (4) 
RV structural abnormalities fulfilling 2010 TFC[47,154]; (5) 
severe tricuspid regurgitation[7]; (6) particular genetic vari-
ants[8,72]; (7) presence of  non-sustained VT[155]; (8) male 
gender[79]; (9) proband status[79]; (10) frequent PVC[79]; and 
(11) presence of  precordial T-wave inversions[79].
It is important to recognize that the use of  appropri-
ate ICD therapy due to sustained VT or VF as a surro-
gate for SCD can result in an overestimation of  this end-
point. Whether in the absence of  arrhythmic syncope or 
significant ventricular arrhythmias the other potential risk 
factors are consistently related to an adverse arrhythmic 
outcome and require prophylactic ICD therapy remains 
to be determined by future studies. Of  note, young pa-
tients may suffer from neurocardiogenic syncope, making 
differential diagnosis difficult and its prognostic value 
elusive. T-waves in the precordial and inferior leads often 
become negative with progression of  AVC and a greater 
extent of  precordial negative T-waves are associated with 
more severe RV dilation and dysfunction[100]. Recently, 
the Johns Hopkins group found that 88% of  patients 
with documented sustained VTA exhibited an abnor-
mal ECG. A total of  122 (84%) subjects demonstrated 
T-wave inversions in the precordial leads with 97 of  them 
extending to lead V3 and beyond, while depolarization 
abnormalities such as epsilon waves were present only in 
a minority of  patients[156]. The same group found that the 
presence of  T-wave inversions in ≥ 3 precordial ECG 
leads was an independent predictor of  adverse events 
during follow-up[79]. An Italian group has also demon-
strated a link between the extent of  negative T-waves 
and ventricular arrhythmic events during follow-up[157]. 
Although a class Ⅱb recommendation, the role of  EPS 
with programmed ventricular stimulation for risk stratifi-
cation in AVC is less well established and conflicting data 
about its prognostic significance exist[45,64,90,158]. Differ-
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ences in the studied patient population may be influenced 
by disease severity[159] and differences in study design may 
have led to discrepant results. A positive family history of  
SCD in asymptomatic patients does not seem to increase 
their individual risk for lethal arrhythmias. Guidelines 
do not support genetic testing for risk stratification in 
AVC[1] and genotype-phenotype correlation studies so far 
have not consistently been able to show that genotyping 
is able to detect mutations specifically associated with 
an increased susceptibility to life-threatening arrhythmic 
events. However, recent data indicates that certain patho-
genic mutations (e.g., plakoglobin in Naxos disease, RyR2 
and TME-43) may increase the risk for SCD[8,62,67]. These 
preliminary results have to be confirmed in larger studies 
and more precise risk stratification tools for asymptom-
atic patients are needed. Novel imaging modalities such 
as strain and three-dimensional echocardiography could 
help to further improve risk stratification[160].
Based on the available data from observational stud-
ies, we suggest classifying patients into three risk catego-
ries[79,161]: (1) high risk: aborted SCD, sustained VT and 
VF, arrhythmic syncope; (2) moderate risk: non-sustained 
VT, severe structural abnormalities of  RV and/or LV, 
presence of  cardiac symptoms, ≥ 3 leads with T-wave 
inversions, frequent PVCs (i.e., > 760 PVC/24 h Holter) 
and severe disease onset age < 35 years; and (3) low risk: 
asymptomatic family members (also despite a positive 
family history of  SCD), < 10 PVC/24 h Holter.
The risk factors listed here have focused largely on 
patients with right-dominant disease. Prognostic factors 
in non-classic disease still remain elusive. Patients should 
be astute for symptoms. Dynamic T-wave inversions, 
ST segment elevation and myocardial biomarker release 
mimicking myocardial infarction should alert the treating 
physicians to think of  a “hot phase” of  AVC. Clinical 
evaluation starting at age 10-12 is suggested for all first- 
and second-degree relatives of  AVC index patients until 
age 60[140]. If  SCD occurs at age < 35, a full postmortem 
autopsy by an expert cardiac pathologist including mo-
lecular autopsy screening for genetic variants should be 
performed.
THERAPY
Physical activity restriction
It is a general consensus that strenuous physical activity 
should be avoided in symptomatic patients with AVC. 
There is no consensus that physical activity should be 
avoided in asymptomatic healthy gene carriers. A recent 
study has shown that endurance exercise and frequent 
exercise increase the risk of  VT/VF and heart failure in 
patients, but also in healthy family members carrying a 
pathogenic desmosomal mutation, supporting exercise 
restriction for these patients[82]. We prudently advise all 
symptomatic patients and healthy gene carriers to re-
frain from practicing competitive sports and strenuous 
physical exercise, not only for reducing the risk of  ven-
tricular arrhythmias, but also to prevent disease onset 
and progression.
Pharmacological therapy
Beta-blockers, amiodarone and sotalol can be effective 
for treatment of  sustained VT or VF in patients with 
AVC. However, they have no proven prognostic benefit 
such as ICD therapy. Wichter et al[107] proved that sotalol 
is highly effective to suppress VT by programmed ven-
tricular stimulation with an efficacy of  68% and 83%, 
respectively, but had no effects on prognosis and SCD. 
Amiodarone was not superior to sotalol in this study and 
is not considered first-line therapy by many clinicians be-
cause of  frequent side effects during long term therapy, 
particularly in young patients. However, recent data from 
the Northern American ARVC registry demonstrated 
amiodarone to confer the greatest efficacy in prevent-
ing ventricular arrhythmias when compared to sotalol or 
beta-blockers. However, mean sotalol doses were lower 
than in the study from Wichter et al[107] and only ten pa-
tients were treated with amiodarone in the American 
study. In clinical practice, beta-blockers, sotalol or amio-
darone are often used as an adjunctive therapy to reduce 
arrhythmia burden in patient with an ICD and amioda-
rone is sometimes combined with beta-blockers in order 
to reduce sympathetic tone and mechanical wall stress[162]. 
Co-administration of  sotalol and amiodarone is not 
recommended due to QT interval prolongation. Hiroi et 
al[163] suggest that carvedilol may control arrhythmias and 
improve LV function in some patients with biventricular 
AVC. Calcium antagonists such as verapamil and mexile-
tin may be effective in some patients to suppress VT but 
data is anecdotal. If  heart failure occurs, standard therapy 
with beta-blockers, angiotensin converting enzyme-
inhibitors and a diuretic should be established, although 
there are no specific studies in patients with AVC[46]. 
Brain natriuretic peptide, C-reactive protein, IL-1β and 
TNF-α as surrogate biomarkers for disease activity, in-
flammation and prognosis have been advocated in AVC 
but await further validation[3,58,164]. AVC patients at later 
stages have an increased risk for thromboembolism[43]. 
The annual incidence of  thromboembolic complications, 
including pulmonary embolism, RVOT thrombosis and 
cerebrovascular events, was 0.5% in a retrospective study 
of  126 patients followed up for a mean period of  99 ± 
64 mo[56]. Anticoagulation is often started by clinicians in 
the presence of  severe ventricular dilation, dysfunction 
and aneurysm, although existing studies do not support 
prophylactic use in those with RV aneurysms. Data for 
the non-classic subtypes are lacking.
Implantable cardioverter-defibrillator
According to the ACC/AHA/HRS 2008 Guidelines for 
Device-Based Therapy of  Cardiac Rhythm Abnormali-
ties and its recent update[165,166], ICD implantation is indi-
cated in patients with structural heart disease who have 
experienced a sustained VTA (secondary prevention, 
Class Ⅰ indication). It is also stated that ICD implanta-
tion is reasonable in AVC patients who have at least one 
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risk factor for SCD (ⅡA indication, level of  evidence C). 
Thus, ICDs constitute a cornerstone for those patients 
and can prolong survival in this population. In fact, a 
large number of  studies has demonstrated that patients 
with AVC who undergo ICD implantation have a high 
likelihood for appropriate ICD therapies[167]. However, 
many questions remain regarding AVC patients and their 
relatives who are at low to moderate risk for SCD. In 
these patients, a lifelong risk for lethal arrhythmias has 
to be weighed against the complication rates of  ICDs, 
inadequate interventions (up to 24% within 5 years), psy-
chological burden and economic costs of  this therapy. 
However, complication rates seem to have declined 
since the use of  third- or fourth-generation defibrilla-
tors. Active and young patients are at particular risk of  
lead displacement and inappropriate discharges for sinus 
tachycardia, including painful shocks and multiple inva-
sive procedures. Thus, indiscriminate device implantation 
cannot be endorsed. Instead, reliable risk stratification is 
of  paramount importance. An ICD with dual chamber 
detection algorithms may be wise in young patients to 
discriminate VT or SVT from sinus tachycardia. The use 
of  antiarrhythmic agents can also reduce the number of  
inadequate interventions due to supraventricular tachyar-
rhythmias. Furthermore, programming of  higher VT/VF 
cut-offs and longer detection intervals can avoid inap-
propriate ICD shocks[168]. Complications of  ICD therapy 
include a risk for perforation caused by thinning of  the 
RV wall, lead dislodgement, R wave under-sensing and 
high pacing thresholds. As patients are young and mobile, 
these risks need particular consideration, although in one 
study, short and long-term risks of  ICD therapy were 
similar to patients without AVC[45].
In our clinical routine, we recommend ICD im-
plantation for all AVC patients who have experienced 
a sustained VTA but we also carefully evaluate ICD 
implantation for primary prevention in probands and 
family members without documented sustained VTA. 
Therefore, we evaluate whether a particular patient (1) 
has high-risk features for SCD during follow-up (see 
list above), (2) whether the patient is willing to take his 
medication regularly and to stop competitive sports (i.e., 
competitive individual events like triathlon or participa-
tion in a competitive sports team), and (3) the patient’s 
preferences. Our threshold for ICD implantation is high-
er in family members and asymptomatic patients owing 
to the fact that previous studies have consistently shown 
that family members are at lower risk of  experiencing 
sustained VTA. A possible explanation for this finding 
is that diagnosis occurs earlier in the disease course and 
once diagnosed, family members are encouraged to give 
up competitive sports. However, more data obtained 
from different well characterized AVC cohorts are neces-
sary to assist clinicians in guiding ICD therapy.
Catheter ablation
Catheter ablation was first applied to treat drug-resistant 
VT. The application of  direct current (DC) termed fulgu-
ration, used DC from a defibrillator to burn myocardial 
sites responsible for abnormal ventricular activation. The 
electric voltage was directly delivered through a catheter 
to the origins of  VT. However, this procedure was as-
sociated with a significant risk of  complications and thus 
rapidly abandoned. Currently accepted indications for 
radiofrequency catheter ablation in patients with AVC 
include drug-refractory VT or incessant VT with fre-
quent ICD shocks. It should be kept in mind that, unlike 
in patients with idiopathic VT where catheter ablation is 
curative, catheter ablation in patients with AVC can only 
improve quality of  life by decreasing the number of  VT 
episodes and PVCs[169]. Catheter ablation can follow a 
trial of  beta-blocker therapy and antiarrhythmic therapy. 
In some patients who do not wish long-term therapy 
with beta-blockers, sotalol and particularly amiodarone, 
catheter ablation can be performed as first line therapy. 
Elimination of  clinical tachycardia can relieve symptoms 
but may not prevent SCD.
Over the last years, mapping and ablation techniques 
have made outstanding progress and nowadays include 
activation, pace and entrainment mapping during VT 
and substrate-based ablation using EAM that can be 
performed via an endocardial and epicardial approach[170]. 
Substrate-based ablation of  PVCs and VT is particularly 
important when conventional mapping during tachy-
cardia is not possible due to hemodynamic instability or 
multiple VT morphologies[171]. Although the initial ap-
proach involved extensive mapping to identify critical 
zones of  slow conduction during VT, this approach has 
recently been replaced by a substrate-based approach. 
Preliminary studies have shown promising results regard-
ing safety, arrhythmia-free survival and reduction of  ICD 
discharges, particularly if  an endocardial and epicardial 
approach are combined[128-131]. In one recent study from 
the Johns Hopkins cohort, the overall freedom from VT 
was 47%, 21% and 15% at 1, 5 and 10 years, respectively. 
Following epicardial VT ablation, the cumulative free-
dom from VT was 64% and 45% at 1 and 5 years. Of  
note, the VT burden decreased from a median of  0.16 
VT episodes per month pre ablation to 0.08 episodes per 
month post ablation[172]. Mid-term and long-term success 
and safety of  these methods have to be demonstrated in 
future studies with larger cohorts.
Surgical methods
Total surgical electrical RV disconnection carries an im-
portant risk of  postoperative RV failure and has been 
practically abandoned[173]. If  severe therapy refractory 
heart failure occurs, ventricular assist devices or heart 
transplantation have to be considered for isolated LV or 
biventricular failure and less frequently isolated RV fail-
ure. Some authors suggest that right heart catheterization 
should be performed in all cases with suspected severe 
RV dysfunction. If  increased filling pressures suggest a 
Fontan-type physiology, the patient may be considered 
for heart transplantation[174].
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CONCLUSION
During the last three decades, our understanding of  AVC 
from a developmental RV dysplasia with substitution 
by adipose tissue has remarkably changed to a mostly 
inherited polygenic disease of  the intercalated disk with 
a broad phenotypic spectrum. Although AVC predomi-
nantly affects the RV, non-classic forms affecting the LV 
or both ventricles are increasingly recognized. A hallmark 
is the early propensity to ventricular arrhythmias associ-
ated with SCD at a young age. Enormous progress in un-
ravelling the genetic and molecular basis of  this complex 
disease, in which environmental factors seem to play a 
pivotal role, has been made in the last years. While prog-
ress in imaging and device therapy has facilitated clini-
cal diagnosis and prevention of  SCD, today’s challenges 
include discovery of  novel genetic and environmental 
factors, early detection of  asymptomatic patients, im-
proved risk stratification, catheter ablation strategies and 
causal therapies to cure the disease[175]. Multicenter, large, 
prospective follow-up studies are planned to improve 
our understanding of  the complex underlying molecular 
mechanisms of  AVC, which may facilitate diagnosis, risk 
stratification and causal therapy.
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